{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:14:44Z","timestamp":1762254884486,"version":"3.37.3"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","award":["2021\/11606-3","2020\/12842-0"],"award-info":[{"award-number":["2021\/11606-3","2020\/12842-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejphar.2024.176723","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T23:56:28Z","timestamp":1717718188000},"page":"176723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"977","author":[{"given":"Keli","family":"Lima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1337-7635","authenticated-orcid":false,"given":"Frederico Lisboa","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9185-3938","authenticated-orcid":false,"given":"Marcella","family":"Cipelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Fernanda Lopes","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego Antonio","family":"Pereira-Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-3181","authenticated-orcid":false,"given":"Wellington Fernandes","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita de C\u00e1ssia","family":"Cavaglieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Nardinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline de Medeiros","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira Deolinda Rodrigues Pereira","family":"Velloso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4751-1428","authenticated-orcid":false,"given":"Israel","family":"Bendit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels Olsen Saraiva","family":"C\u00e2mara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Jacob","family":"Schuringa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Agostinho","family":"Machado-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Magalh\u00e3es","family":"Rego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2024.176723_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1873-3468.14237","article-title":"Expanding role of PI5P4Ks in cancer: a promising druggable target","volume":"596","author":"Arora","year":"2022","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejphar.2024.176723_bib2","article-title":"Pharmacological inhibition of PI5P4Kalpha\/beta disrupts cell energy metabolism and selectively kills p53-null tumor cells","volume":"118","author":"Chen","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2024.176723_bib3","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.3390\/ijms20122929","article-title":"Next-generation sequencing in acute lymphoblastic Leukemia","volume":"20","author":"Coccaro","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176723_bib4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.cell.2013.09.057","article-title":"Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors","volume":"155","author":"Emerling","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2024.176723_bib5","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.bbalip.2015.02.014","article-title":"PIP4K and the role of nuclear phosphoinositides in tumour suppression","volume":"1851","author":"Fiume","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2024.176723_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2019.150951","article-title":"Adult acute lymphoblastic Leukemia: treatment and management updates","volume":"35","author":"Gregory","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.ejphar.2024.176723_bib7","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1073\/pnas.1219333110","article-title":"Phosphatidylinositol 5-phosphate 4-kinase (PIP4K) regulates TOR signaling and cell growth during Drosophila development","volume":"110","author":"Gupta","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2024.176723_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12032-017-1038-7","article-title":"Genetic susceptibility in childhood acute lymphoblastic leukemia","volume":"34","author":"Gutierrez-Camino","year":"2017","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejphar.2024.176723_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1194\/jlr.M082149","article-title":"PIP4K2A regulates intracellular cholesterol transport through modulating PI(4,5)P(2) homeostasis","volume":"59","author":"Hu","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejphar.2024.176723_bib10","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ejphar.2024.176723_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1323897","article-title":"Lipid kinases PIP5Ks and PIP4Ks: potential drug targets for breast cancer","volume":"13","author":"Jin","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2024.176723_bib12","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/s41467-017-02287-5","article-title":"Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality","volume":"8","author":"Kitagawa","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2024.176723_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cancergen.2019.04.002","article-title":"PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia","volume":"233\u2013234","author":"Lima","year":"2019","journal-title":"Cancer Genet."},{"key":"10.1016\/j.ejphar.2024.176723_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41408-022-00747-w","article-title":"The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy","volume":"12","author":"Lima","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejphar.2024.176723_bib15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.ejphar.2024.176723_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.molcel.2018.03.037","article-title":"Phosphatidylinositol-5-Phosphate 4-kinases regulate cellular lipid metabolism by facilitating autophagy","volume":"70","author":"Lundquist","year":"2018","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejphar.2024.176723_bib17","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2024.176723_bib18","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1080\/10428194.2019.1605071","article-title":"Recent advances in the treatment of acute lymphoblastic leukemia","volume":"60","author":"Rafei","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejphar.2024.176723_bib19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.chembiol.2020.02.003","article-title":"Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors","volume":"27","author":"Sivakumaren","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejphar.2024.176723_bib20","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejphar.2024.176723_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade8641","article-title":"PI5P4Kalpha supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor inhibition","volume":"9","author":"Triscott","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejphar.2024.176723_bib22","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2013-04-495390","article-title":"Novel childhood ALL susceptibility locus BMI1-PIP4K2A is specifically associated with the hyperdiploid subtype","volume":"121","author":"Walsh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2024.176723_bib23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/jnci\/djt042","article-title":"Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations","volume":"105","author":"Xu","year":"2013","journal-title":"J. Natl. Cancer Inst."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924004114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924004114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T19:03:41Z","timestamp":1719687821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924004114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":23,"alternative-id":["S0014299924004114"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176723","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"176723"}}